- Dr. Krieg joins Sarepta (SRPT) from RaNA Therapeutics where he was CEO since co-founding the company in 2011. Prior to that, he was CSO of Pfizer's Oligonucleotide Therapeutics Unit from 2008-11.
- Krieg: "The recent resurgence in the field of RNA therapeutics has been due in part to the excitement around Sarepta’s exon skipping therapies and their potential for patients with Duchenne."
- Press release
- Shares -1.6% AH
Sarepta names Art Krieg as CSO
Jan 9 2014, 16:31 ET